[ Price : $8.95]
FDA accepts for priority review an Ionis Pharmaceuticals supplemental NDA for olezarsen for treating severe hypertriglyceridemia.[ Price : $8.95]
Eli Lilly reports favorable efficacy data on its investigational oral GLP-1 receptor agonist orforglipron, showing significantly g...[ Price : $8.95]
FDA commissioner Marty Makary defends the agencys scientific standards and personnel, particularly CBER director Vinay Prasad, ami...[ Price : $8.95]
FDA awards Boehringer Ingelheim Pharmaceuticals an accelerated approval for Hernexeos (zongertinib) for certain adults with unrese...[ Price : $8.95]
FDA prepares to roll out a new bonus program that will reward drug and biologic reviewers for completing high-quality reviews ahea...[ Price : $8.95]
An FDA Voices post by FDA chief operating officer Barclay Butler says the agencys ability to uphold the gold standard of regulator...[ Price : $8.95]
A rare disease advocacy group tells Congress to increase FDA oversight, warning that inconsistent use of regulatory flexibility an...[ Price : $8.95]
FDA approves a Sanofi and Regeneron Pharmaceuticals BLA supplement for Dupixent (dupilumab) and its use for treating adults and ch...